Skip to main content
Top
Published in: Surgery Today 9/2014

Open Access 01-09-2014 | Original Article

Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution

Authors: Konosuke Moritani, Hirotoshi Hasegawa, Koji Okabayashi, Yoshiyuki Ishii, Takashi Endo, Yuko Kitagawa

Published in: Surgery Today | Issue 9/2014

Login to get access

Abstract

Purpose

The prognostic differences between right- and left-sided colon cancer are controversial. This study aimed to clarify the clinical difference between right- and left-sided colon cancer.

Methods

We enrolled 820 patients with stage I/II/III colon cancer who underwent radical surgery with curative intent. We explored the impact of the tumor location on the postoperative disease-free survival (DFS) rate using the univariate and multivariate analyses.

Results

Right-sided disease occurred in 399 of the 820 patients. The mean follow-up period was 55.8 ± 34.9 months. The pathological stage distribution was as follows: stage I 261 patients; stage II 283; and stage III 251. There were no significant differences in the five-year DFS of the overall populations (right 88.6 %; left 89.4 %; P = 0.231). The subgroup analyses demonstrated that patients with stage I right-sided colon cancer had a significantly better 5-year DFS rate than did those with left-sided disease (100 vs. 95.2 %, P = 0.034). There were no significant differences in the distributions of the first recurrent sites (P = 0.559).

Conclusions

The tumor location may contribute to postoperative tumor recurrence. However, these effects were inconsistent across tumor stages. Our results provide a better understanding of the prognostic disparity between tumor locations; this may improve patient consent and postoperative surveillance.
Literature
1.
go back to reference Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum. 1988;31:33–41.PubMedCrossRef Wiggers T, Arends JW, Volovics A. Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum. 1988;31:33–41.PubMedCrossRef
2.
go back to reference Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986;57:1866–70.PubMedCrossRef Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986;57:1866–70.PubMedCrossRef
3.
go back to reference Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.PubMedCrossRef Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.PubMedCrossRef
4.
go back to reference Suttie SA, Shaikh I, Mullen R, et al. Outcome of right and left sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13:884–9.PubMedCrossRef Suttie SA, Shaikh I, Mullen R, et al. Outcome of right and left sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13:884–9.PubMedCrossRef
6.
go back to reference Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388–94.PubMedCentralPubMedCrossRef Meguid RA, Slidell MB, Wolfgang CL, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388–94.PubMedCentralPubMedCrossRef
7.
go back to reference Wray CM, Ziogas A, Hinojosa MW, et al. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52:1359–66.PubMedCrossRef Wray CM, Ziogas A, Hinojosa MW, et al. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52:1359–66.PubMedCrossRef
8.
go back to reference Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.PubMedCrossRef Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.PubMedCrossRef
9.
go back to reference Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.PubMedCrossRef Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.PubMedCrossRef
10.
go back to reference Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13:3831–9.PubMedCrossRef Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13:3831–9.PubMedCrossRef
11.
go back to reference Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.PubMedCrossRef Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.PubMedCrossRef
12.
go back to reference Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–33.PubMedCrossRef Fransen K, Klintenas M, Osterstrom A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–33.PubMedCrossRef
13.
go back to reference Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002;137:129–31. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002;137:129–31.
14.
go back to reference Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25(Suppl 1):S49–56.PubMedCrossRef Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol. 2010;25(Suppl 1):S49–56.PubMedCrossRef
15.
go back to reference Gross CP, Andersen MS, Krumholz HM, et al. Relation between medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296:2815–22.PubMedCrossRef Gross CP, Andersen MS, Krumholz HM, et al. Relation between medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296:2815–22.PubMedCrossRef
16.
go back to reference Park JI, Yu CS, Kim CW, et al. Prognosis and recurrent patterns of sporadic primary colon cancers according to location. J. Korean Soc.Coloproctol. 2009;25:221–26. Park JI, Yu CS, Kim CW, et al. Prognosis and recurrent patterns of sporadic primary colon cancers according to location. J. Korean Soc.Coloproctol. 2009;25:221–26.
17.
go back to reference Kauh J, Brawley OW, Berger M. Racial disparities in colorectal cancer. Curr Probl Cancer. 2007;31:123–33.PubMedCrossRef Kauh J, Brawley OW, Berger M. Racial disparities in colorectal cancer. Curr Probl Cancer. 2007;31:123–33.PubMedCrossRef
18.
go back to reference Okabayashi K, Hasegawa H, Ishii Y, et al. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients. Cancer Chemother Pharmacol. 2009;63:501–7.PubMedCrossRef Okabayashi K, Hasegawa H, Ishii Y, et al. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients. Cancer Chemother Pharmacol. 2009;63:501–7.PubMedCrossRef
19.
go back to reference Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.PubMedCrossRef Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.PubMedCrossRef
20.
go back to reference Yoshida D, Ikeda Y, Waki K, et al. Different incidence of synchronous liver metastasis between proximal and distal colon cancer. Surg Today. 2012;42(5):426–30.PubMedCrossRef Yoshida D, Ikeda Y, Waki K, et al. Different incidence of synchronous liver metastasis between proximal and distal colon cancer. Surg Today. 2012;42(5):426–30.PubMedCrossRef
Metadata
Title
Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution
Authors
Konosuke Moritani
Hirotoshi Hasegawa
Koji Okabayashi
Yoshiyuki Ishii
Takashi Endo
Yuko Kitagawa
Publication date
01-09-2014
Publisher
Springer Japan
Published in
Surgery Today / Issue 9/2014
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0748-5

Other articles of this Issue 9/2014

Surgery Today 9/2014 Go to the issue